Sanofi invests to make France its world class center of excellence in vaccine research and production
16 Juin 2020 - 12:00PM
Sanofi invests to make France its world class center of excellence
in vaccine research and production
Sanofi invests to make France its world class center of
excellence in vaccine research and production
- Sanofi will invest more than half a billion euros to create a
state-of-the-art vaccine production site (Neuville sur Saône) and a
new research center (Marcy-l'Etoile) dedicated to vaccines
- The investments will strengthen Sanofi’s leadership and
capacity to advance the research of new innovative vaccines and
produce them on a massive scale, in line with the corporate
strategy
- The innovative technologies of these new facilities will also
provide Sanofi with the flexibility and agility needed to quickly
respond to future pandemic risks
PARIS – June 16, 2020 – Sanofi
today detailed plans on how the Company will make significant
investments in France to increase its vaccines research and
production capacities, and contribute in responding to future
pandemic risks. Aligned with its corporate strategy presented last
December, Sanofi will invest €610 million to create a new
production site and research center in France with both dedicated
to vaccines.
“Sanofi’s heart beats in France. We have a long
history and exceptional teams working throughout the country,
embodying our strong values. By investing in a new industrial site
and a R&D center, Sanofi positions France at the core of its
strategy, aiming to make France a world-class center of excellence
in vaccine research and production," said Paul Hudson, Chief
Executive Officer at Sanofi. “Sanofi is a major healthcare player
in France, in Europe, and worldwide. It is our responsibility to
focus our resources and expertise against the current pandemic, but
also to invest in preparing for future ones. We welcome the ongoing
collaboration and commitment of the French authorities who we have
been working alongside with the last several months to achieve
this.”
Sanofi will invest in vaccine production in
France and create its Evolutive Vaccine Facility (EVF) in Neuville
sur Saône. This state-of-the-art industrial site will utilize the
latest innovative vaccine production technologies. The project
represents an investment of €490 million over a five-year period,
and is expected to create 200 new jobs. Sanofi’s investment has
been made possible thanks to the support and the close
collaboration with French authorities over the last few months.
The building of this plant will enable Sanofi
Pasteur, Sanofi's global entity dedicated to vaccines, to be the
first pharmaceutical manufacturer to benefit from such an
industrial tool and to secure vaccine supplies in the event of new
pandemics. EVF is a new type of factory designed around a central
unit housing several fully digital production modules that make it
possible to produce three to four vaccines simultaneously, versus
only one in current industrial sites. This modularity will make it
possible to prioritize the production of a specific vaccine in a
more timely manner based on public health issues.
Sanofi has also committed to investing €120
million to create a new R&D center in France at the Sanofi
Pasteur site in Marcy-l'Etoile to develop future vaccines. This
state-of-the-art digital facility will house highly specialized
laboratories that will enable the development of vaccines against
emerging diseases and pandemic risks. The facility will become a
world reference for pre-clinical research and pharmaceutical and
clinical development. Sanofi expresses its gratitude to the
Auvergne-Rhône-Alpes French region for its support in this
project.
Sanofi shares the French authorities’ vision for
a sovereign Europe in healthcare and announced last February the
creation of a new industry-leading European company to provide
active pharmaceutical ingredients. The company today stands ready
to cooperate with France and the European Union (EU) on other
projects which will provide the EU with extra vaccine (EVF
extension project) or monoclonal antibody (cell culture tanks
installation and start-up project) production capabilities. These
supplementary capabilities can be leveraged by the EU and other
pharma companies in the event of a healthcare crisis.
A world leader in vaccines
Sanofi, with its global vaccine entity Sanofi
Pasteur, is a leading vaccine developer and manufacturer. Sanofi
offers a portfolio of vaccines to protect children, adolescents,
and adults from diseases such as influenza, infectious diseases,
and endemic diseases.
With 16,000 employees and an international
network of 12 industrial sites dedicated to vaccine manufacturing,
including three in France (Marcy-l'Etoile, Neuville sur Saône,
Val-de-Reuil), Sanofi Pasteur’s vaccines protect more than half a
billion people in the world.
Sanofi is the world’s third largest vaccine
producer in value terms, with a unique footprint in the Rhône-Alpes
region and nearly 7,200 employees working for the Sanofi Pasteur
site in Lyon, a global center of excellence in the field of
vaccines.
A major player in the healthcare sector
in France
Sanofi plays a major role in meeting the health
needs of patients and supporting their healthcare. In France,
Sanofi provides more than 200 medicines, vaccines, and health
products.
With a unique footprint of 33 sites in France,
including 22 industrial sites and approximately 25,000 employees,
Sanofi represents a quarter of the workforce of the entire French
pharmaceutical industry.
Sanofi is France’s leading private R&D
investor, with more than €2 billion spent each year researching new
treatments for patients, totaling half of the private research
effort in France. Nearly 5,000 researchers and scientists work in a
variety of therapeutic areas, mainly focusing on oncology,
immuno-oncology, vaccines and rare diseases.
Sanofi also has one third of its global
production in France, making it one of the country’s leading
exporters. Sanofi has invested €3 billion in its French production
sites over the past five years, including €1.5 billion to
accelerate the build-up of biotechnologies in the country.
On the front line in the fight against
Covid-19
Since the beginning of the pandemic, Sanofi has
played a leading role in the fight against COVID-19. In
collaboration with health authorities and international partners,
Sanofi is one of the only companies in the world to work on the
search for COVID-19 vaccine candidates by exploring two different
technological approaches.
- The recombinant DNA technology, in collaboration with GSK, is a
type of vaccine that makes it possible to industrially produce very
large quantities of antigens, the proteins injected to stimulate
the immune system’s response to the virus.
- The messenger RNA technology technology, in collaboration with
TranslateBio, is a vaccine that leads the human body’s cells to
manufacture the virus antigens to which the immune system will
react.
Sanofi is also committed to making its vaccine
accessible to all and around the world.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations Contact Quentin Vivant Tel.: +33
(0)1 53 77 46 46 mr@sanofi.com |
Investor
Relations Contact Felix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly, and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2019. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements. |
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024